Innovative tools to detect Glioblastoma GBM exosomes
Gl.EXO is about innovative tools to detect Glioblastoma (GBM) exosomes and to have a timely, accurate and non-invasive diagnosis of GBM. Several studies have underlined the role of exosome cell–cell communication in different tumo...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BrEXo-Apt
Non invasive and accurate diagnosis and treatment of breast...
188K€
Cerrado
STIC-GBM
Spatio-temporal dynamics of immune circuitry in glioblastoma...
174K€
Cerrado
MICRONEX
Microbioreactor platforms as in vivo like systems to probe t...
1M€
Cerrado
GLIOBID
Guiding glioblastoma treatments by decrypting tumor biomecha...
284K€
Cerrado
VESSEL CO-COPTION
Vessel co option and radioresistance in glioblastoma
1M€
Cerrado
Información proyecto Gl.EXO
Duración del proyecto: 26 meses
Fecha Inicio: 2020-04-03
Fecha Fin: 2022-06-30
Líder del proyecto
PERCUROS BV
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
176K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Gl.EXO is about innovative tools to detect Glioblastoma (GBM) exosomes and to have a timely, accurate and non-invasive diagnosis of GBM. Several studies have underlined the role of exosome cell–cell communication in different tumour types, including GBM, suggesting their potential use as diagnostic/prognostic/predictive biomarkers and therapeutic agents. In fact, evidences have demonstrated that the release of GBM exosomes plays a key role in cancer growth and progression by modulating tumor microenviroment and affecting angiogenesis, tumour migration, immune escape and drug resistance. However, GBM exosomes-enriched proteins characterization started only since few years and studies still lack informations on GBM exosomes cargo and their impact on cancer progression. Moreover, the identification of specific biomarkers able to discriminate between cancer exosomes from normal exosomes and tools for their detection are necessary and still unknown. Therefore, by inhibiting GBM exosomes uptake, Gl.EXO will contribute to hamper GBM progression in many cancer aspects. To address this issue, Gl.EXO aims to use nucleic acid-based aptamers as innovative tools to detect specifically GBM exosomes.